India approves AstraZeneca and local Covid vaccines, rollout in weeks

Published January 3, 2021
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters

India’s drugs regulator on Sunday gave final approval for the emergency use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.

The world’s second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech’s Covaxin administered under stricter conditions given that no efficacy data has been released for it.

The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42 per cent, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response”, said Drugs Controller General of India VG Somani.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded Covishield, while Bharat Biotech has teamed up with the government run Indian Council of Medical Research.

“Vaccines of Serum [Institute of India] and Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement at a press conference. Somani did not take questions.

Both vaccines will be administered in two doses and stored at two to eight degrees Celsius, he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.

Somani explained that the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains”.

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.

“All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “Covishield, India’s first Covid-19 vaccine, is approved, safe, effective and ready to roll out in the coming weeks.”

Opinion

New engagement
Updated 19 Apr 2021

New engagement

Better Pak-India ties mean a better regional outcome.
Inequality and ideology
19 Apr 2021

Inequality and ideology

Hunger and want, and the constant reminder of inequality,may condition religious mobilisation, but they are not solely sufficient.
Ties of sentiment
19 Apr 2021

Ties of sentiment

Pakistan-UK relations have been remarkably stable and increasingly energised by the Pakistani diaspora.

Editorial

19 Apr 2021

Vaccine shortfall

THE hope that the slew of Covid-19 vaccinations approved for use since the end of last year would vanquish the ...
Another package
Updated 19 Apr 2021

Another package

Sindh has not seen much development worth the name during the PPP’s more than decade-long rule in the province.
19 Apr 2021

Cricket triumph

TEAM Pakistan have a number of reasons to rejoice after their 3-1 T20 series win over hosts South Africa on Friday....
18 Apr 2021

More cabinet changes

PRIME MINISTER Imran Khan has reshuffled his cabinet yet again in what is obviously another attempt to shore up his...
Blocking social media
Updated 18 Apr 2021

Blocking social media

FOR four hours this week, all social media platforms in the country were shut down, a measure the government said ...
18 Apr 2021

Peasant rights in Sindh

IN a seminar held in Nawabshah recently, the Sindh Human Rights Commission and Hari Welfare Association reiterated a...